Announcements Trials

Browse Landscape

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Gastrointestinal 2 Thoracic 1 Head & Neck 1 Genitourinary 1 CNS 1 Breast 1

Conditions

HR+HER2- Advanced Breast Cancer 1

Interventions

Trastuzumab 732 Paclitaxel 695 Cyclophosphamide 647 Docetaxel 560 Capecitabine 486 Letrozole 437 Fulvestrant 400 Carboplatin 398 Doxorubicin 341 Tamoxifen 308 Anastrozole 279 pembrolizumab 274 exemestane 258 Epirubicin 251 pertuzumab 240 Radiotherapy 239 palbociclib 224 Bevacizumab 222 Gemcitabine 215 Vinorelbine 197 Lapatinib 181 130-nm albumin-bound paclitaxel 172 Magnetic Resonance Spectroscopy 164 Albumin-Bound Paclitaxel 157 eribulin 154 Surveys and Questionnaires 152 Exercise 151 Drug Therapy 141 Taxes 134 Fluorouracil 133

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Drug Therapy, Combination × Breast × Clear all

NCT06148506 2025-12-05

ValerEE

Novartis

Active not recruiting

HR+HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡